Key result
Thoracic lymphadenopathy on pre-TAVI CT is linked to ~66% higher 4-year mortality risk.
Why the study?
Do incidental thoracic findings on preoperative CT scans affect mid-term survival in patients undergoing TAVI?
Cohort (n=976)
Do incidental thoracic findings on preoperative CT scans affect mid-term survival in patients undergoing TAVI?
Hazard Ratio: 1.66 (95% CI 1.19–2.31)
p-value: p=0.001
Incidental thoracic lymphadenopathy on pre-TAVI CT scans is associated with reduced mid-term survival, whereas solitary pulmonary nodules do not significantly impact survival.
Thoracic LAP on pre-TAVI CT was associated with worse 4-year survival; leaves open whether targeted workup alters outcomes in this high-risk group.
OBJECTIVES: Preoperative computed tomography (CT) scans for transcatheter aortic valve implantation (TAVI) are used routinely. In elderly high-risk patients, incidental radiographic findings are frequently reported. The aim of this study was to investigate the impact of auxiliary findings on the patients' mid-term survival, which might affect the treatment strategy. METHODS: Between March 2011 and April 2016, all radiological reports of contrast-enhanced CT scans of 976 patients scheduled for TAVI were analysed retrospectively for incidental thoracic findings including solitary pulmonary nodules (SPN) and thoracic lymphadenopathy (LAP). The minimum follow-up period was 1 year after TAVI. RESULTS: The median age of all patients was 79 years; 51.9% (n = 507) were women. Approximately 37% (n = 361) of patients showed 1 of the determined findings. An SPN ≥5 mm was diagnosed in 16.4% (n = 160) of patients. Four of them developed lung cancer and 2 nodules were identified as metastases during follow-up. In addition, 12% (n = 117) of the patients had thoracic LAP. Whereas SPN had no significant effect on the overall survival rate, evidence of LAP turned out to be a statistically significant factor regarding 4-year survival (P = 0.001; hazard ratio 1.66; 95% confidence internal 1.19-2.31). CONCLUSIONS: SPN ≥5 mm were detected in 16.4% of patients scheduled for TAVI. Nevertheless, the incidence of lung cancer was low and the effect on survival in this high-risk group of patients was statistically not significant. In contrast, thoracic LAP had a significant negative effect on survival. It needs to be proven if the outcome of this cohort can be enhanced by further diagnostics and therapy.
No takes yet. Share an insight, caveat, or question.
Markowiak et al. (2018) conducted a cohort in Scheduled for transcatheter aortic valve implantation (TAVI) (n=976). Thoracic lymphadenopathy (LAP) vs. No thoracic LAP was evaluated on 4-year survival (HR 1.66, 95% CI 1.19-2.31, p=0.001). Thoracic lymphadenopathy detected on preoperative CT before TAVI was associated with significantly reduced 4-year survival (HR 1.66; 95% CI 1.19-2.31; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: